8,258 Shares in Intrexon Corporation (NYSE:XON) Acquired by SG Americas Securities LLC
SG Americas Securities LLC purchased a new stake in Intrexon Corporation (NYSE:XON) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 8,258 shares of the biotechnology company’s stock, valued at approximately $164,000.
A number of other institutional investors have also modified their holdings of XON. State Board of Administration of Florida Retirement System raised its stake in Intrexon Corporation by 0.9% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 75,606 shares of the biotechnology company’s stock valued at $1,837,000 after buying an additional 707 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Intrexon Corporation by 670.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 83,514 shares of the biotechnology company’s stock valued at $2,029,000 after buying an additional 72,675 shares in the last quarter. GSA Capital Partners LLP bought a new stake in Intrexon Corporation during the fourth quarter valued at approximately $232,000. Norges Bank bought a new stake in Intrexon Corporation during the fourth quarter valued at approximately $17,300,000. Finally, Teachers Advisors LLC raised its stake in Intrexon Corporation by 6.4% in the fourth quarter. Teachers Advisors LLC now owns 50,172 shares of the biotechnology company’s stock valued at $1,219,000 after buying an additional 3,005 shares in the last quarter. Institutional investors own 84.39% of the company’s stock.
Shares of Intrexon Corporation (XON) traded up 1.55% on Friday, hitting $21.65. The stock had a trading volume of 496,088 shares. Intrexon Corporation has a 12 month low of $18.41 and a 12 month high of $32.90. The firm has a 50 day moving average of $23.55 and a 200 day moving average of $22.08. The stock’s market cap is $2.59 billion.
Intrexon Corporation (NYSE:XON) last posted its earnings results on Wednesday, May 10th. The biotechnology company reported ($0.26) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.22) by $0.04. The firm had revenue of $53.70 million for the quarter, compared to analysts’ expectations of $49.08 million. Intrexon Corporation had a negative return on equity of 21.19% and a negative net margin of 76.32%. The firm’s revenue for the quarter was up 23.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.55) earnings per share. On average, equities analysts forecast that Intrexon Corporation will post ($0.91) earnings per share for the current fiscal year.
Several research firms have commented on XON. Zacks Investment Research lowered Intrexon Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. BidaskClub upgraded Intrexon Corporation from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 15th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $42.17.
About Intrexon Corporation
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Stock Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related stocks with our FREE daily email newsletter.